Table 4.
Broadly reactive seroprotection and cross-reactivity between IBV lineages induced by the Yamagata component.
| RESPONSES BASED ON YAM COMPONENT |
YAMAGATA ** |
VICTORIA ** |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Flu Season | Group * | n-value | Age | # | % | D0 | D21 | Change | D0 | D21 | Change |
| 2014–2015 | GROUP 1 (SN ≫ SN) | 44 | 18–34 | 0 | 0% | - | - | - | - | - | - |
| 38 | 35–49 | 0 | 0% | - | - | - | - | - | - | ||
| 32 | 50–64 | 0 | 0% | - | - | - | - | - | - | ||
| 35 | 65–85 | 1 | 3% | 57% | 57% | 0% | 100% | 100% | 0% | ||
| GROUP 2 (SN ≫ SP) | 44 | 18–34 | 1 | 2% | 0% | 86% | 86% | 50% | 100% | 50% | |
| 38 | 35–49 | 2 | 5% | 71% | 86% | 14% | 100% | 100% | 0% | ||
| 32 | 50–64 | 10 | 31% | 56% | 89% | 33% | 83% | 90% | 8% | ||
| 35 | 65–85 | 6 | 17% | 45% | 76% | 31% | 75% | 75% | 0% | ||
| GROUP 3 (SP ≫ SP) | 44 | 18–34 | 36 | 82% | 96% | 99% | 3% | 90% | 97% | 8% | |
| 38 | 35–49 | 31 | 82% | 90% | 96% | 6% | 91% | 95% | 4% | ||
| 32 | 50–64 | 16 | 50% | 93% | 96% | 4% | 88% | 95% | 8% | ||
| 35 | 65–85 | 20 | 57% | 84% | 91% | 7% | 86% | 89% | 2% | ||
| GROUP 4 (SP ≫ SC) | 44 | 18–34 | 7 | 16% | 92% | 100% | 8% | 86% | 100% | 14% | |
| 38 | 35–49 | 5 | 13% | 77% | 100% | 23% | 80% | 100% | 20% | ||
| 32 | 50–64 | 6 | 19% | 74% | 98% | 24% | 83% | 92% | 8% | ||
| 35 | 65–85 | 8 | 23% | 93% | 100% | 7% | 81% | 91% | 9% | ||
| 2015–2016 | GROUP 1 (SN ≫ SN) | 48 | 18–34 | 2 | 4% | 36% | 64% | 29% | 75% | 100% | 25% |
| 39 | 35–49 | 1 | 3% | 86% | 86% | 0% | 75% | 100% | 25% | ||
| 28 | 50–64 | 1 | 4% | 43% | 57% | 14% | 50% | 50% | 0% | ||
| 35 | 65–85 | 1 | 3% | 43% | 43% | 0% | 100% | 100% | 0% | ||
| GROUP 2 (SN ≫ SP) | 48 | 18–34 | 4 | 8% | 71% | 100% | 29% | 94% | 100% | 6% | |
| 39 | 35–49 | 11 | 28% | 74% | 97% | 23% | 86% | 100% | 14% | ||
| 28 | 50–64 | 7 | 25% | 57% | 94% | 37% | 75% | 100% | 25% | ||
| 35 | 65–85 | 6 | 17% | 64% | 93% | 29% | 71% | 83% | 13% | ||
| GROUP 3 (SP ≫ SP) | 48 | 18–34 | 35 | 73% | 100% | 100% | 0% | 89% | 99% | 9% | |
| 39 | 35–49 | 20 | 51% | 98% | 100% | 2% | 93% | 98% | 5% | ||
| 28 | 50–64 | 13 | 46% | 92% | 98% | 5% | 90% | 94% | 4% | ||
| 35 | 65–85 | 21 | 60% | 94% | 99% | 5% | 81% | 95% | 14% | ||
| GROUP 4 (SP ≫ SC) | 48 | 18–34 | 7 | 15% | 96% | 100% | 4% | 79% | 100% | 21% | |
| 39 | 35–49 | 7 | 18% | 94% | 100% | 6% | 86% | 93% | 7% | ||
| 28 | 50–64 | 7 | 25% | 96% | 100% | 4% | 75% | 89% | 14% | ||
| 35 | 65–85 | 7 | 20% | 90% | 100% | 10% | 86% | 100% | 14% | ||
| 2016–2017 | GROUP 1 (SN ≫ SN) | 39 | 18–34 | 1 | 3% | 14% | 43% | 29% | 100% | 100% | 0% |
| 36 | 35–49 | 1 | 3% | 29% | 57% | 29% | 100% | 100% | 0% | ||
| 30 | 50–64 | 6 | 20% | 29% | 60% | 31% | 71% | 79% | 8% | ||
| 33 | 65–85 | 5 | 15% | 26% | 54% | 29% | 70% | 75% | 5% | ||
| GROUP 2 (SN ≫ SP) | 39 | 18–34 | 2 | 5% | 71% | 86% | 14% | 88% | 100% | 13% | |
| 36 | 35–49 | 11 | 31% | 39% | 86% | 47% | 75% | 91% | 16% | ||
| 30 | 50–64 | 7 | 23% | 31% | 86% | 55% | 68% | 82% | 14% | ||
| 33 | 65–85 | 7 | 21% | 31% | 84% | 53% | 82% | 93% | 11% | ||
| GROUP 3 (SP ≫ SP) | 39 | 18–34 | 31 | 79% | 97% | 100% | 2% | 90% | 94% | 4% | |
| 36 | 35–49 | 20 | 56% | 96% | 99% | 3% | 93% | 96% | 4% | ||
| 30 | 50–64 | 15 | 50% | 94% | 100% | 6% | 92% | 92% | 0% | ||
| 33 | 65–85 | 17 | 52% | 83% | 95% | 12% | 78% | 93% | 15% | ||
| GROUP 4 (SP ≫ SC) | 39 | 18–34 | 5 | 13% | 94% | 100% | 6% | 95% | 100% | 5% | |
| 36 | 35–49 | 4 | 11% | 96% | 100% | 4% | 100% | 100% | 0% | ||
| 30 | 50–64 | 2 | 7% | 71% | 100% | 29% | 88% | 88% | 0% | ||
| 33 | 65–85 | 4 | 12% | 93% | 100% | 7% | 69% | 100% | 31% | ||
* Seronegative (SN) = < 1:40, Seropositive (SP) = ≥ 1:40, Seroconversion (SC) = fourfold rise in titer
** percent change of post-vaccination recognition of viruses; darker shading = largest increases
(other than the vaccine component/recommendation each season: Yamagata = 7 viruses, Victoria = 4 viruses)